MA28215A1 - Formes galeniques de l'oxycodone à libération contrôlée pour administration orale une fois par jour - Google Patents
Formes galeniques de l'oxycodone à libération contrôlée pour administration orale une fois par jourInfo
- Publication number
- MA28215A1 MA28215A1 MA28979A MA28979A MA28215A1 MA 28215 A1 MA28215 A1 MA 28215A1 MA 28979 A MA28979 A MA 28979A MA 28979 A MA28979 A MA 28979A MA 28215 A1 MA28215 A1 MA 28215A1
- Authority
- MA
- Morocco
- Prior art keywords
- profiles
- once
- galenic forms
- oral administration
- controlled release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
FORMES GALÉNIQUES DE L'OXYCODONE À LIBÉRATION CONTRÔLÉE POUR ADMINISTRATION ORALE UNE FOIS PAR JOUR La présente invention concerne des formulations d'oxycodone qui produisent des profils plasma tiques en équilibre dynamique in vivo pratiquement plats. Les niveaux de tolérance associés à de tels profils et les niveaux de tolérance associés aux profils biphasiques se sont révélés ne pas être statistiquement différents. Les profils p.iasmatiques en équilibre dynamique in vivo pratiquement plats sont produits par des formes galéniques ayant des profils de libération in vit.ro pratiquement de l'ordre de zéro. De tels prot ils de libération produisent des niveaux faibles de Cmaz in vivo avec une dose unique qui peuvent diminuer la probabilité des effets secondaires néfastes.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51588003P | 2003-10-29 | 2003-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA28215A1 true MA28215A1 (fr) | 2006-10-02 |
Family
ID=34549453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28979A MA28215A1 (fr) | 2003-10-29 | 2006-04-28 | Formes galeniques de l'oxycodone à libération contrôlée pour administration orale une fois par jour |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1677798A2 (fr) |
JP (1) | JP2007509979A (fr) |
KR (1) | KR20060108690A (fr) |
CN (1) | CN1933837A (fr) |
AU (1) | AU2004285547A1 (fr) |
BR (1) | BRPI0415639A (fr) |
CA (1) | CA2546691A1 (fr) |
EC (1) | ECSP066534A (fr) |
IL (1) | IL175193A0 (fr) |
MA (1) | MA28215A1 (fr) |
NO (1) | NO20062398L (fr) |
RU (1) | RU2006118323A (fr) |
WO (1) | WO2005041968A2 (fr) |
ZA (1) | ZA200604310B (fr) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU764453B2 (en) | 1999-10-29 | 2003-08-21 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
CN101317825A (zh) | 2000-10-30 | 2008-12-10 | 欧罗赛铁克股份有限公司 | 控释氢可酮制剂 |
US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
UA81224C2 (uk) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
DE102004032051A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
BRPI0906467C1 (pt) | 2008-01-25 | 2021-05-25 | Gruenenthal Gmbh | forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada |
US9226907B2 (en) | 2008-02-01 | 2016-01-05 | Abbvie Inc. | Extended release hydrocodone acetaminophen and related methods and uses thereof |
LT2273983T (lt) | 2008-05-09 | 2016-10-25 | Grünenthal GmbH | Tarpinės miltelių kompozicijos gamybos būdas ir galutinė kieta dozavimo forma naudojant purškalo kietinimo stadija |
AU2010275754B2 (en) | 2009-07-22 | 2014-05-15 | Grünenthal GmbH | Tamper-resistant dosage form for oxidation-sensitive opioids |
EP2456427B1 (fr) | 2009-07-22 | 2015-03-04 | Grünenthal GmbH | Formule de dosage pharmaceutique extrudée thermofusible à libération prolongée |
US20110150989A1 (en) * | 2009-12-22 | 2011-06-23 | Mallinkckrodt Inc. | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans |
WO2011124953A2 (fr) * | 2010-04-07 | 2011-10-13 | Lupin Limited | Compositions pharmaceutiques à libération contrôlée de tapentadol |
WO2012028319A1 (fr) | 2010-09-02 | 2012-03-08 | Grünenthal GmbH | Forme pharmaceutique inviolable comportant un sel inorganique |
MX2013002293A (es) | 2010-09-02 | 2013-05-09 | Gruenenthal Gmbh | Forma de dosificacion resistente a alteracion que comprende un polimero anionico. |
BR112014002022A2 (pt) | 2011-07-29 | 2017-02-21 | Gruenenthal Gmbh | comprimido resistente à violação proporcionando liberação de fármaco imediata |
LT2736497T (lt) | 2011-07-29 | 2017-11-10 | Grünenthal GmbH | Sugadinimui atspari tabletė, pasižyminti greitu vaisto atpalaidavimu |
US20130225697A1 (en) | 2012-02-28 | 2013-08-29 | Grunenthal Gmbh | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
AU2013248351B2 (en) | 2012-04-18 | 2018-04-26 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
JP6466417B2 (ja) | 2013-05-29 | 2019-02-06 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 二峰性放出プロファイルを有する改変防止(tamper−resistant)剤形 |
CA2907950A1 (fr) | 2013-05-29 | 2014-12-04 | Grunenthal Gmbh | Forme pharmaceutique inviolable contenant une ou plusieurs particules |
EA032465B1 (ru) | 2013-07-12 | 2019-05-31 | Грюненталь Гмбх | Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления |
AU2014356581C1 (en) | 2013-11-26 | 2020-05-28 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
CN106572980A (zh) | 2014-05-12 | 2017-04-19 | 格吕伦塔尔有限公司 | 包含他喷他多的防篡改即释胶囊制剂 |
CN106456550A (zh) | 2014-05-26 | 2017-02-22 | 格吕伦塔尔有限公司 | 避免乙醇剂量倾泻的多颗粒 |
AU2016251854A1 (en) | 2015-04-24 | 2017-10-19 | Grunenthal Gmbh | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
JP2018526414A (ja) | 2015-09-10 | 2018-09-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護 |
JP6875501B2 (ja) | 2016-08-10 | 2021-05-26 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Aktプロテインキナーゼ阻害剤を含む薬学的組成物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5914131A (en) * | 1994-07-07 | 1999-06-22 | Alza Corporation | Hydromorphone therapy |
UA81224C2 (uk) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
US20040010000A1 (en) * | 2002-04-29 | 2004-01-15 | Ayer Atul D. | Methods and dosage forms for controlled delivery of oxycodone |
JP2005528423A (ja) * | 2002-05-31 | 2005-09-22 | アルザ・コーポレーシヨン | オキシコドンの変動性投薬用量の浸透圧的送達のための剤形および組成物 |
-
2004
- 2004-10-28 KR KR1020067010336A patent/KR20060108690A/ko not_active Application Discontinuation
- 2004-10-28 WO PCT/US2004/036132 patent/WO2005041968A2/fr active Application Filing
- 2004-10-28 AU AU2004285547A patent/AU2004285547A1/en not_active Abandoned
- 2004-10-28 CN CNA2004800394188A patent/CN1933837A/zh active Pending
- 2004-10-28 CA CA002546691A patent/CA2546691A1/fr not_active Abandoned
- 2004-10-28 JP JP2006538357A patent/JP2007509979A/ja not_active Withdrawn
- 2004-10-28 RU RU2006118323/15A patent/RU2006118323A/ru unknown
- 2004-10-28 BR BRPI0415639-0A patent/BRPI0415639A/pt not_active IP Right Cessation
- 2004-10-28 EP EP04817492A patent/EP1677798A2/fr not_active Withdrawn
-
2006
- 2006-04-25 IL IL175193A patent/IL175193A0/en unknown
- 2006-04-28 MA MA28979A patent/MA28215A1/fr unknown
- 2006-04-28 EC EC2006006534A patent/ECSP066534A/es unknown
- 2006-05-26 NO NO20062398A patent/NO20062398L/no not_active Application Discontinuation
- 2006-05-26 ZA ZA200604310A patent/ZA200604310B/en unknown
Also Published As
Publication number | Publication date |
---|---|
NO20062398L (no) | 2006-07-27 |
KR20060108690A (ko) | 2006-10-18 |
CN1933837A (zh) | 2007-03-21 |
WO2005041968A2 (fr) | 2005-05-12 |
ECSP066534A (es) | 2006-11-24 |
BRPI0415639A (pt) | 2006-12-12 |
RU2006118323A (ru) | 2007-12-10 |
WO2005041968A3 (fr) | 2006-06-22 |
JP2007509979A (ja) | 2007-04-19 |
CA2546691A1 (fr) | 2005-05-12 |
IL175193A0 (en) | 2008-04-13 |
ZA200604310B (en) | 2007-11-28 |
EP1677798A2 (fr) | 2006-07-12 |
AU2004285547A1 (en) | 2005-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA28215A1 (fr) | Formes galeniques de l'oxycodone à libération contrôlée pour administration orale une fois par jour | |
MA38576A1 (fr) | Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières | |
RS56252B1 (sr) | Jednodnevne formulacije oksikodona | |
BR0008059A (pt) | Composições de valdecoxib | |
NO20052739L (no) | CCR5-antagonister som medikamenter | |
WO2003070236A3 (fr) | Derives de pyrazole tricyclique, procedes de leur preparation et leur utilisation en tant qu'agents anti-tumoraux | |
WO2004054581A3 (fr) | Composes de cyclohexyle utiles en tant qu'antagonistes du ccr5 | |
EP1820503A3 (fr) | Dérivés d'aminoindazole actifs en tant qu'inhibiteurs de la kinase, leur procédé de préparation et compositions pharmaceutiques les contenant | |
CY1105648T1 (el) | Filbanserin για την θεραπεια εξτραπυραμιδικων διαταραχων κινησης | |
ATE407928T1 (de) | Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung | |
MA31668B1 (fr) | Polypeptides, domaines variables d'anticorps et antagonistes | |
MXPA04003666A (es) | Uso de flibanserina para tratamiento de trastornos sexuales. | |
TNSN07476A1 (fr) | Derives de n-(pyridine -2- yl) - sulfonamide | |
WO2008019996A3 (fr) | Formulations de flibansérine et leur procédé de fabrication | |
HK1087336A1 (en) | Pharmaceutical composition comprising lumiracoxib | |
AU2003296992A1 (en) | Pyrrolidine and azetidine compounds as ccr5 antagonists | |
SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
HRP20080612T3 (en) | Combination of tenofovir, ritonavir and tmc114 | |
JP2008540405A5 (fr) | ||
MA29278B1 (fr) | Composition pharmaceutique comprenant un derive de l'indolylmaleimide | |
WO2007075572A3 (fr) | Inhibiteurs a base de purine oralement actifs de la proteine de choc thermique 90 | |
WO2004064757A3 (fr) | Agents facilitant l'absorption | |
CA3242402A1 (fr) | Lipides destines a etre utilises dans des formulations de nanoparticules lipidiques | |
DK1653923T3 (da) | Oral afleveringssystem omfattende en bivæsket skum | |
RU2004112422A (ru) | Роувастатин в преддеменционных состояниях |